225Ac-DOTATATE靶向α治疗用于177Lu-DOTATATE治疗后稳定或难治性胃肠胰神经内分泌肿瘤的疗效与安全性初步临床经验
这项前瞻性研究纳入32例177Lu-DOTATATE治疗后稳定或进展的转移性胃肠胰神经内分泌肿瘤患者,给予225Ac-DOTATATE(100 kBq/kg体重)靶向α治疗,每8周一次。中位随访8个月,24例可评估形态学缓解者中15例部分缓解、9例稳定,无疾病进展或死亡,血浆嗜铬粒蛋白显著下降。短期结果显示该治疗对177Lu-DOTATATE难治或已达最大疗程者是 promising 的选择。
要点
- 225Ac-DOTATATE靶向α治疗每8周一次,剂量100 kBq/kg体重。
- 24例可评估患者中15例部分缓解、9例稳定,中位随访8个月无进展或死亡。
- 血浆嗜铬粒蛋白水平治疗后显著下降(P < 0.0001)。
核心结论
- 短期临床结果表明225Ac-DOTATATE靶向α治疗是177Lu-DOTATATE难治或已达最大疗程患者的 promising 治疗选择。
研究设计与样本
- 前瞻性研究,2018年4月至2019年3月纳入32例转移性胃肠胰神经内分泌肿瘤患者,其中14例(44%)为177Lu-DOTATATE治疗后稳定,18例(56%)为进展。
- 所有患者接受225Ac-DOTATATE(100 kBq/kg体重)系统性靶向α治疗,间隔8周。
- 主要终点为客观缓解(RECIST 1.1和功能学M.D. Anderson标准),次要终点包括生化缓解(ITMO标准)、不良事件(CTCAE v5.0)和生活质量(EORTC QLQ-GI.NET21问卷)。
主要发现
- 24/32例患者可评估形态学缓解,其中15例部分缓解、9例稳定。
- 中位随访8个月(范围2-13个月)期间无疾病进展或死亡记录。
- 225Ac-DOTATATE治疗后血浆嗜铬粒蛋白水平显著下降(P < 0.0001)。
关键数值与推荐
- 225Ac-DOTATATE给药剂量为100 kBq/kg体重,间隔8周。
- 客观缓解采用RECIST 1.1和功能学M.D. Anderson标准评估。
- 生化缓解依据意大利肿瘤内科试验(ITMO)标准,不良事件依据CTCAE v5.0。
临床怎么用
- 对于177Lu-DOTATATE治疗后稳定或进展的转移性胃肠胰神经内分泌肿瘤患者,可考虑225Ac-DOTATATE靶向α治疗。
- 治疗期间需按CTCAE v5.0监测不良事件,并可用EORTC QLQ-GI.NET21评估生活质量。
局限性
- 随访时间短(中位8个月,范围2-13个月),仅报告短期结果。
- 形态学缓解仅在24/32例患者中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to investigate and present the early results on the efficacy, safety, and quality of life of 225Ac-DOTATATE targeted alpha therapy (TAT) in patients with advanced, progressive, 177Lu-DOTATATE refractory, and somatostatin receptor (SSTR) expressing metastatic GEP-NETs. METHODS: In this prospective study, we recruited patients with metastatic GEP-NETs who were stable or progressive disease on 177Lu-DOTATATE therapy. Systemic TAT using 225Ac-DOTATATE was performed in all the patients with 225Ac-DOTATATE (100 kBq/kg body weight) at an interval of 8 weeks. The primary end point was to assess the objective response (measured by RECIST 1.1 and functional M.D. Anderson criteria). The secondary end points included biochemical response assessment as per the Italian Trials in Medical Oncology (ITMO), adverse event profile as per CTCAE v5.0, and clinical response assessment by the quality of life (assessed with EORTC QLQ-GI.NET21 patient-based questionnaire). RESULTS: Between April 2018 and March 2019, 32 patients (17 females, 15 males, mean age 52 ± 9.2 years, 35-72 years) with either stable disease after completing 177Lu-DOTATATE therapy (14, 44%) or progressive disease on 177Lu-DOTATATE therapy (18, 56%) were included in the study. The morphological response was assessed in 24/32 patients that revealed partial remission in 15 and stable disease in 9. There was no documented disease progression or deaths in the median follow-up of 8 months (range 2-13 months). There was a significant decrease in the plasma chromogranin level post-225Ac-DOTATATE therapy (P < 0.0001). CONCLUSION: Our short-term clinical results indicate 225Ac-DOTATATE TAT as a promising treatment option which adds a new dimension in patients who are refractory to 177Lu-DOTATATE therapy or have reached the maximum prescribed cycles of 177Lu-DOTATATE therapy.
引用
- Ballal S, Yadav MP, Bal C, et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2019. PMID: 31707430. doi:10.1007/s00259-019-04567-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。